公开(公告)号：US20040235935A1

公开(公告)日：2004-11-25

申请号：US10480131

申请日：2004-06-08

Inventor： Francis Vanderbist ,  Antonio Sereno ,  Philippe Baudier

IPC: A61K031/401 ,  A61K031/366 ,  A61K031/225 ,  A61K009/14

CPC classification number: A61K47/44 ,  A61K9/4858 ,  A61K31/22 ,  A61K31/366 ,  A61K2300/00

Abstract: Oral stable liquid pharmaceutical compositions comprising at least a statin derivative suspended in at least an oily excipient. The said composition allows to obtain a high bioavailability of the drug after oral administration to mammals. A process for manufacturing the said compositions.

Abstract translation: 口服稳定的液体药物组合物，其至少包含悬浮在至少一种油性赋形剂中的他汀类衍生物。 所述组合物允许在口服给予哺乳动物后获得药物的高生物利用度。 一种制备所述组合物的方法。

公开(公告)号：US20040213782A1

公开(公告)日：2004-10-28

申请号：US10768266

申请日：2004-01-30

Applicant: Pharmacia Corporation

Inventor： Martin B. Wax

IPC: A61K039/395 ,  A61K031/225 ,  A61K031/401

CPC classification number: A61K45/06

Abstract: The present invention provides compositions and methods for lowering intraocular pressure in a subject. More particularly, the invention provides a combination therapy for the treatment of an ophthalmic disorder mediated by an elevated intraocular pressure comprising administering to a subject an aquaporin modulating agent in combination with an aqueous humor modulating agent, where the aqueous humor modulating agent lowers intraocular pressure by a pathway other than the modulation of aquaporin.

Abstract translation: 本发明提供降低受试者眼内压的组合物和方法。 更具体地，本发明提供了用于治疗由眼内压升高所引起的眼科障碍的组合疗法，其包括向受试者施用水通道调节剂与房水调节剂的组合，其中房水调节剂通过以下方式降低眼内压： 除了水通道蛋白调节以外的途径。

公开(公告)号：US20040186164A1

公开(公告)日：2004-09-23

申请号：US10763309

申请日：2004-01-23

Inventor： Wayne H. Kaesemeyer

IPC: A61K031/401 ,  A61K031/366 ,  A61K031/198 ,  A61K031/225

CPC classification number: A61L31/16 ,  A61K31/198 ,  A61K31/21 ,  A61K31/22 ,  A61K31/225 ,  A61K31/365 ,  A61K31/366 ,  A61K31/40 ,  A61K31/401 ,  A61K31/41 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/675 ,  A61K38/18 ,  A61K45/06 ,  A61L2300/114 ,  A61L2300/416 ,  A61K31/195 ,  A61K2300/00

Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.

Abstract translation: 用L-精氨酸和增强L-精氨酸生物转化为NO的试剂的混合物处理血管。 与再狭窄相关的事件预计将大大减少并且预防由于损伤导致再狭窄的发生率降低。

公开(公告)号：US20040167085A1

公开(公告)日：2004-08-26

申请号：US10476816

申请日：2004-04-13

Inventor： Deepak Hedge ,  Sushrut Kulkarni

IPC: A61K031/7008 ,  A61K031/401 ,  A61K031/366 ,  A61K031/225

CPC classification number: A61K31/22 ,  A61K9/2018

Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.

Abstract translation: 一种药物组合物，其包含作为活性成分的HMG-CoA还原酶抑制剂和氨基糖。

公开(公告)号：US20040138302A1

公开(公告)日：2004-07-15

申请号：US10740042

申请日：2003-12-18

Applicant: Wyeth Holdings Corporation

Inventor： Ping Cai ,  Fangming Kong ,  Pamela Fink Charbonneau ,  Mark Edward Ruppen

IPC: C11D001/28 ,  A61K031/255 ,  A61K031/225

CPC classification number: C07C229/30 ,  A61K31/155 ,  C07C225/14 ,  C07C233/31 ,  C07C279/10 ,  C07C279/22 ,  C07C305/14 ,  C12P13/02

Abstract: This disclosure describes antifungal antibiotics designated Hygroscopene A, Hygroscopene B and Hygroscopene C to their production by fermentation, to methods for recovery and concentration from the crude solutions, to a process for purification and to new analogs of Hygroscopene A, Hygroscopene B and Hygroscopene C prepared by synthetic procedures.

Abstract translation: 本公开内容描述了抗真菌抗生素，其命名为通过发酵生产的抗真菌抗生素，通过发酵生产，用于从粗制溶液中回收和浓缩的方法，纯化方法以及制备的吸湿ene ene A，吸湿ene ene B和Hy ene ene C的新类似物 通过合成程序。

公开(公告)号：US20040138295A1

公开(公告)日：2004-07-15

申请号：US10742367

申请日：2003-12-19

Applicant: Lek Pharmaceuticals d.d.

Inventor： Zlatko Pflaum ,  Mateja Salobir ,  Zdenka Jerala ,  Aleksander Resman

IPC: A61K031/366 ,  A61K031/225

CPC classification number: A61K9/1688

Abstract: The present invention relates to a novel solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, with a particle size D(0.9) between 15 and 100 nullm and a specific particle surface area between 1 and 4 m2/g, and to the process for its preparation. The present invention also relates to the method for production of lovastatin and simvastatin with the size of crystals which are suitable for the preparation of the pharmaceutical formulation of the present invention. The novel solid pharmaceutical formulation is useful for treating hypercholesterolemia and hyperlipidemia.

Abstract translation: 本发明涉及分别含有粒径D（0.9）在15-100μm之间的洛伐他汀和辛伐他汀的新型固体药物制剂，特异性颗粒表面积在1至4m 2 / g之间，而对于 其准备过程。 本发明还涉及适用于制备本发明的药物制剂的具有晶体尺寸的洛伐他汀和辛伐他汀的生产方法。 新型固体药物制剂可用于治疗高胆固醇血症和高脂血症。

公开(公告)号：US20040132814A1

公开(公告)日：2004-07-08

申请号：US10738196

申请日：2003-12-17

Inventor： Jan-Erik Loefroth ,  Jonas Oedman

IPC: A61K031/225 ,  A61K009/14

CPC classification number: A61K9/2054 ,  A61K9/2004 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/5078 ,  A61K31/22 ,  A61K31/404

Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.

Abstract translation: 本发明涉及用于持续释放的药物组合物，其包含HMG-CoA还原酶抑制剂氟伐他汀的水溶性盐作为活性成分，所述组合物选自基质制剂，扩散控制的膜包衣制剂; 及其组合。

公开(公告)号：US20040110835A1

公开(公告)日：2004-06-10

申请号：US10680042

申请日：2003-10-06

Inventor： Brian Keller

IPC: A61K031/225 ,  C11B001/00

CPC classification number: C08G65/3322 ,  A23L33/115 ,  A61K31/23 ,  C07C69/30 ,  Y10S514/825 ,  Y10S514/886 ,  Y10S514/944 ,  Y10S514/962

Abstract: The present invention comprises a group of related lipid molecules, and methods for their use, that maybe used to treat inflammation and certain inflammation related diseases. The group of related lipid molecules are capable of inhibiting certain enzyme systems including phospholipase A2, and cyclooxygenase-2. The group of related lipid molecules of the invention may be characterized by specific structural characteristics, or by specific biological activity, including inhibition of the previously listed enzymes.

Abstract translation: 本发明包括一组相关的脂质分子及其使用的方法，其可用于治疗炎症和某些炎症相关疾病。 该组相关脂质分子能够抑制某些酶系统，包括磷脂酶A2和环氧合酶-2。 本发明的相关脂质分子组可以通过特定的结构特征或特定的生物学活性来表征，包括先前列出的酶的抑制。

公开(公告)号：US20040109881A1

公开(公告)日：2004-06-10

申请号：US10658522

申请日：2003-09-08

Inventor： Raymond Bertholet ,  Wang Junkuan ,  Pierre Lambelet ,  Heribert Watzke ,  Zdenek Kratky

IPC: C11B001/00 ,  A61K031/225

CPC classification number: A61Q19/00 ,  A23C11/04 ,  A23D9/00 ,  A23K10/10 ,  A23K20/158 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A23V2002/00 ,  A61K8/67 ,  A61K8/92 ,  C11B1/025 ,  C11B1/06 ,  C11B1/10 ,  C12P7/6472 ,  A23V2250/1942 ,  A23V2250/1862 ,  A23V2250/1874 ,  A23V2250/187 ,  A23V2250/1868 ,  A23V2250/18 ,  A23V2250/202 ,  A23V2250/208

Abstract: Stable oil containing long-chain polyunsaturated essential fatty acids (LC-PUFAs) in the form of triacylglycerols, in particular arachidonic acid (ARA), dihomogammalinolenic acid (DHGLA), docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA). Such an oil may be prepared by bringing a carrier oil into contact with a biomass obtained from the culture of a microorganism, in particular a fungus or a microalga containing the acids ARA, DHGLA, DHA or EPA. These oils can be incorporated into the composition of a foodstuff, of a cosmetic or pharmaceutical product.

Abstract translation: 含有三酰基甘油，特别是花生四烯酸（ARA），二氨基葡糖醛酸（DHGLA），二十二碳六烯酸（DHA）或二十碳五烯酸（EPA））形式的长链多不饱和必需脂肪酸（LC-PUFA）的稳定油。 这样的油可以通过使载体油与从微生物，特别是含有ARA，DHGLA，DHA或EPA的微生物或微藻的培养物获得的生物质接触来制备。 这些油可以掺入到食品，化妆品或药物产品的组合物中。

公开(公告)号：US20040106591A1

公开(公告)日：2004-06-03

申请号：US10699195

申请日：2003-10-31

Inventor： Linda M. Pacioretty ,  John G. Babish

IPC: A61K031/555 ,  A61K031/385 ,  A61K031/225 ,  A61K031/22

CPC classification number: A61K31/28 ,  A61K31/045 ,  A61K31/198 ,  A61K31/20 ,  A61K31/426 ,  A61K31/43 ,  A61K2300/00

Abstract: Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.

Abstract translation: 公开了用于治疗或预防由HIV-1感染的抗逆转录病毒治疗引起的脂肪分布不均或高脂血症的组合物。 组合物含有共轭脂肪酸或醇和选自含硫醇化合物和生物可利用形式的三价铬的至少一种。 通过施用包含共轭脂肪酸或共轭脂肪醇的组合物和至少一种选自含硫醇化合物和生物可利用形式的三价药物来治疗患有HIV相关脂肪分布异常或高脂血症的受试者的方法 铬类似地提供。